Posted on 12/11/2015
Despite reimbursement and regulatory challenges, the outlook for the U.S. IVD industry seems rosy, thanks to molecular diagnostics, boomers, and Obamacare.
Although in vitro diagnostics (IVD) companies continue to grapple with regulatory and reimbursement obstacles, factors such as breakthrough technologies, a swelling aging population, a rebounding economy, and even the Affordable Care Act (ACA) are contributing to a relatively rosy outlook for the U.S. IVD sector. In fact, these positive forces are expected to boost the U...